Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease

Background and objectives: Treatment with sodium–glucose co-transporter 2 (SGLT2) inhibitors decrease tubular reabsorption of phosphate, which may explain the reduction of bone mineral density and an excess of bone fractures observed in some studies with this class of drugs. Since an increased risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Masajtis-Zagajewska, Anna, Hołub, Tomasz, Pęczek, Katarzyna, Makówka, Agnieszka, Nowicki, Michał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705759/
https://www.ncbi.nlm.nih.gov/pubmed/34946298
http://dx.doi.org/10.3390/medicina57121352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705759/
https://www.ncbi.nlm.nih.gov/pubmed/34946298
http://dx.doi.org/10.3390/medicina57121352

Ejemplares similares